Your browser is no longer supported. Please, upgrade your browser.
CLSN [NASD]
Celsion Corporation
Index- P/E- EPS (ttm)-0.69 Insider Own0.54% Shs Outstand86.56M Perf Week-21.48%
Market Cap95.79M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float64.80M Perf Month-53.71%
Income-21.50M PEG- EPS next Q- Inst Own5.50% Short Float5.34% Perf Quarter17.78%
Sales0.50M P/S191.58 EPS this Y12.90% Inst Trans-28.13% Short Ratio0.17 Perf Half Y58.19%
Book/sh0.49 P/B2.16 EPS next Y13.30% ROA-53.60% Target Price- Perf Year-10.17%
Cash/sh0.19 P/C5.57 EPS next 5Y- ROE-110.60% 52W Range0.43 - 6.50 Perf YTD49.09%
Dividend- P/FCF- EPS past 5Y45.80% ROI-80.60% 52W High-83.69% Beta2.04
Dividend %- Quick Ratio2.80 Sales past 5Y0.00% Gross Margin- 52W Low146.23% ATR0.17
Employees27 Current Ratio2.80 Sales Q/Q0.00% Oper. Margin- RSI (14)30.08 Volatility11.34% 9.89%
OptionableYes Debt/Eq0.27 EPS Q/Q34.30% Profit Margin- Rel Volume0.21 Prev Close1.19
ShortableYes LT Debt/Eq0.21 EarningsMar 19 BMO Payout- Avg Volume19.91M Price1.06
Recom2.00 SMA20-33.21% SMA50-43.62% SMA200-13.02% Volume4,272,799 Change-10.92%
Jul-16-20Downgrade Oppenheimer Outperform → Perform
Jul-14-20Downgrade Dawson James Buy → Neutral
Oct-04-17Upgrade Maxim Group Hold → Buy $7
Apr-10-17Resumed Rodman & Renshaw Buy $1.50
Nov-10-16Downgrade Maxim Group Buy → Hold
Jul-12-16Resumed H.C. Wainwright Buy $3
Jan-19-16Reiterated Maxim Group Buy $12 → $9
Jul-15-15Initiated Maxim Group Buy $12
Jan-10-14Resumed HC Wainwright Buy $5 → $8
Aug-16-12Reiterated Griffin Securities Buy $10 → $18
Feb-16-12Initiated Brean Murray Buy $7
Oct-26-11Initiated Rodman & Renshaw Mkt Outperform $6
Nov-11-09Initiated Needham Buy $7
Apr-05-21 05:00PM  
Apr-01-21 09:23AM  
08:30AM  
Mar-31-21 08:00AM  
Mar-19-21 09:15AM  
08:45AM  
Mar-12-21 08:45AM  
Mar-05-21 12:00PM  
08:32AM  
Mar-02-21 08:45AM  
Mar-01-21 12:46PM  
Feb-26-21 08:45AM  
Feb-25-21 07:26PM  
05:00PM  
04:10PM  
02:45PM  
11:34AM  
08:45AM  
Feb-23-21 08:00AM  
Feb-22-21 07:30AM  
05:17AM  
Feb-12-21 08:30AM  
03:43AM  
Feb-11-21 08:30AM  
Feb-09-21 08:00AM  
Feb-06-21 05:16PM  
Jan-29-21 08:32AM  
Jan-28-21 08:00AM  
Jan-26-21 05:00PM  
Jan-22-21 08:40AM  
Jan-21-21 11:53PM  
10:01AM  
08:47AM  
Dec-29-20 01:20PM  
10:30AM  
09:37AM  
09:10AM  
Dec-28-20 12:55PM  
09:24AM  
Dec-26-20 09:00AM  
Dec-24-20 05:02PM  
11:00AM  
Dec-22-20 05:02PM  
Dec-19-20 01:00PM  
08:30AM  
Dec-18-20 11:49AM  
Dec-16-20 11:50PM  
05:00PM  
02:40PM  
Dec-15-20 05:02PM  
12:27PM  
Dec-14-20 08:50PM  
Dec-13-20 12:40AM  
Dec-12-20 10:00AM  
Dec-11-20 03:15PM  
08:53AM  
Dec-10-20 04:20PM  
01:25PM  
Dec-09-20 10:15PM  
05:00PM  
11:45AM  
Dec-08-20 12:16PM  
12:20AM  
Dec-07-20 11:54PM  
09:15PM  
Dec-05-20 04:07PM  
03:45PM  
Dec-03-20 05:17PM  
12:45PM  
11:30AM  
04:00AM  
Dec-02-20 07:00PM  
Dec-01-20 01:30PM  
Nov-30-20 10:47PM  
Nov-28-20 11:50PM  
Nov-27-20 03:10PM  
01:00PM  
01:20AM  
Nov-26-20 06:31PM  
10:00AM  
12:01AM  
Nov-25-20 06:30PM  
Nov-24-20 07:00PM  
07:00PM  
04:05PM  
Nov-23-20 10:30PM  
Nov-22-20 02:09AM  
Nov-20-20 06:00PM  
Nov-19-20 11:00AM  
10:02AM  
Nov-18-20 09:45PM  
08:00PM  
12:56PM  
Nov-17-20 01:10PM  
Nov-16-20 10:02PM  
09:15AM  
08:44AM  
08:30AM  
Nov-15-20 01:20PM  
Nov-14-20 04:15PM  
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.